Increasing the tumour targeting of antitumour drugs through anlotinib-mediated modulation of the extracellular matrix and the RhoA/ROCK signalling pathway

• Autors principals: Xuedan Han (Autor), Jialei Liu (Autor), Yidong Zhang (Autor), Eric Tse (Autor), Qiyi Yu (Autor), Yu Lu (Autor), Yi Ma (Autor), Lufeng Zheng (Autor)
• Format: Llibre
• Publicat: Elsevier, 2024-08-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Anlotinib has strong antiangiogenic effects and leads to vessel normalization. However, the "window period" characteristic in regulating vessel normalization by anlotinib cannot fully explain the long-term survival benefits achieved through combining it with other drugs. In this study, thr...